文献速递眼底病与葡萄膜炎

不同形态糖尿病性黄斑水肿对兰尼单抗应答不足患者玻璃体内地塞米松植入剂治疗

INTRAVITREAL DEXAMETHASONE IMPLANTATION IN PATIENTS WITH DIFFERENT MORPHOLOGICAL DIABETIC MACULAR EDEMA HAVING INSUFFICIENT RESPONSE TO RANIBIZUMAB.
PubMed 文献 · Retina · 2018-01-01

这项回顾性研究评估了31例(35眼)对兰尼单抗应答不足的持续性糖尿病性黄斑水肿患者接受单次玻璃体内地塞米松植入剂治疗的效果,黄斑水肿分为弥漫性视网膜增厚(10眼)、囊样黄斑水肿(13眼)和浆液性视网膜脱离(12眼)三型。结果显示三组最佳矫正视力在第六个月前无差异,但第六个月时弥漫性视网膜增厚组最佳矫正视力显著更优(P=0.008);黄斑中心凹厚度在第六个月前浆液性视网膜脱离组显著优于其他两组(P=0.001),但第六个月时三组间无统计学差异。研究期间4例(11.4%)患者需使用抗青光眼药物。

要点

  • 第六个月时弥漫性视网膜增厚组最佳矫正视力显著优于其他两组(P=0.008)。
  • 第六个月前浆液性视网膜脱离组黄斑中心凹厚度显著优于其他两组(P=0.001)。
  • 研究期间4例(11.4%)患者需使用抗青光眼药物。

核心结论

  • 作者认为治疗算法应根据糖尿病性黄斑水肿的形态而不同,但需要更多数据才能给出具体推荐。

研究设计与样本

  • 回顾性研究,纳入31例(35眼)对兰尼单抗应答不足的持续性糖尿病性黄斑水肿患者,接受单次玻璃体内地塞米松植入剂注射。
  • 黄斑水肿分为三型:弥漫性视网膜增厚(n=10)、囊样黄斑水肿(n=13)、浆液性视网膜脱离(n=12)。
  • 主要结局指标为最佳矫正视力和黄斑中心凹厚度。

主要发现

  • 三个亚组在年龄和性别方面相似(P>0.05)。
  • 浆液性视网膜脱离亚组糖尿病总病程显著更短(P=0.01)。
  • 第六个月前三个亚组间最佳矫正视力无差异;第六个月时弥漫性视网膜增厚组最佳矫正视力显著更优(P=0.008)。
  • 第六个月前浆液性视网膜脱离组黄斑中心凹厚度在统计学上优于弥漫性视网膜增厚组和囊样黄斑水肿组(P=0.001);第六个月时三组间黄斑中心凹厚度无任何统计学差异。
  • 研究期间4例(11.4%)患者需使用抗青光眼药物。

临床怎么用

  • 作者认为治疗算法应根据糖尿病性黄斑水肿的形态而不同,但需要更多数据才能给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant in resistant diabetic macular edema that have different morphological types. METHODS: In this retrospective study, 31 patients (35 eyes) with persistent diabetic macular edema, who underwent a single injection of dexamethasone implant, were evaluated. Diabetic macular edema was classified into three types: diffuse retinal thickening (n = 10), cystoid macular edema (n = 13), and serous retinal detachment (n = 12). Primary outcome measures were best corrected visual acuity, and central macular thickness. RESULTS: The three subgroups were similar in terms of age and gender (P > 0.05). Total duration of diabetes was significantly less in the serous retinal detachment subgroup (P = 0.01). There were no differences in the best corrected visual acuity between the three subgroups until the sixth month. However, the best corrected visual acuity was significantly better in the diffuse retinal thickness subgroup at the sixth month (P = 0.008). Regarding the central macular thickness values, it was statistically better in serous retinal detachment than in diffuse retinal thickening and cystoid macular edema subgroups till the sixth month (P = 0.001). However, at the sixth month, there was not any statistical difference between subgroups regarding central macular thickness values. Antiglaucomatous agents were required in 4 (11.4%) patients throughout the study. CONCLUSION: Treatment algorithms should differ according to the morphology of diabetic macular edema; however, more data is needed to give specific recommendations.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kaldırım H, Yazgan S, Atalay K, et al. INTRAVITREAL DEXAMETHASONE IMPLANTATION IN PATIENTS WITH DIFFERENT MORPHOLOGICAL DIABETIC MACULAR EDEMA HAVING INSUFFICIENT RESPONSE TO RANIBIZUMAB. Retina. 2018. PMID: 28426623. doi:10.1097/IAE.0000000000001648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。